慢性丙型肝炎不同抗病毒药物治疗的临床观察分析  

Clinical observation on the antiviral treatment of chronic hepatitis C with different drugs

作　　者：冯婥[1] 杜宇[1] 黄远明[1] 周宇辰[2] 何纬[3] 叶晓光[1] 周元平[4] 

机构地区：[1]广州医学院第二附属医院感染病科,广东广州510260 [2]广州医学院2004级临床医学二系 [3]广州医学院附属荔湾医院感染病科 [4]南方医科大学南方医院

出　　处：《中西医结合肝病杂志》2008年第4期200-202,共3页Chinese Journal of Integrated Traditional and Western Medicine on Liver Diseases

基　　金：国家自然科学基金面上项目(No.3406167730771899)

摘　　要：目的:评价慢性丙型肝炎(CHC)不同抗病毒药物及方案的疗效与副作用,以优化慢性丙型肝炎治疗策略、提高临床治愈率。方法:动态观察、比较经典治疗组(普通干扰素α/利巴韦林)与聚乙二醇化干扰素α-2 a(PEG-IFNα-2 a)利/巴韦林组的临床疗效及副作用。结果:PEG-IFNα-2 a利/巴韦林组与经典治疗组比较,其快速应答率高,早期的不良反应相对少而轻,对不良反应的总体耐受性好,疗效高并且稳定。结论:PEG-IFNα-2 a联合利巴韦林方案较优,治疗中密切观察处理不良反应、施行个体化治疗方案具有提高总体疗效的意义。Objective： To evaluate the treatment protocols, efficacy and side effects of anti-HCV drugs, which could be helpful for optimizing the treatment strategy and increasing clinical recovery rate of chronic hepatitis C. Methods： The clinical efficacy and side effects in both routine treatment group （interferon α/ribavirin, B group） and PEG-IFNα-2a/ribavirin treatment group （ A group） were carefully observed, followed up and compared. Results ： Higher rate of rapid viral response, less adverse reactions in the early stage, more tolerant and higher total curative rate were observed in PEG-IFNα-2a/ribavirin treatment group than that in B group. Conclusion： The results indicated it＇ s better using PEG-IFNα-2a/ribavirin to chronic hepatitis C. It might be helpful for increasing the total curative rate. observing, dealing with the adverse reactions ; and using individual anti-viral ther apy strategy.

关 键 词：肝炎 丙型 慢性 干扰素 治疗 

分 类 号：R512.63[医药卫生—内科学] R978.7[医药卫生—临床医学]